Halozyme Therapeutics, Inc.
HALOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHalozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and. Valued at $9.23B, HALO is a mid-cap name in its sector. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Market Cap
$9.23B
Beta
0.84
P/E (TTM)
27.21
P/E (Fwd)
7.85
EPS (TTM)
$2.86
EPS (Fwd)
$9.91
ROE
99.4%
ROA
22.1%
Cash
$318.6M
Total Debt
$2.18B
Free CF
$228.1M
52W Change
37.8%
Annual Financials
Cash vs Debt
Halozyme Therapeutics, Inc. carries $2.18B in total debt against $318.6M in cash reserves — debt is roughly 6.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $228.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 99.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 22.1% further supports the picture of efficient asset utilization. Revenue has grown from $660.1M (2022) to $1.40B (2025), reflecting a 112% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HALO.